Testing HRS-5635 to improve hepatitis B treatment
Part of Infections clinical trials.
This study tests whether adding a new drug called HRS-5635 to your current hepatitis B medicine works better than your current treatment alone. You may qualify if your hepatitis B is already controlled with antiviral pills and your viral levels are very low.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Diagnosed with chronic hepatitis B at least 6 months ago
- Currently taking a nucleos(t)ide analogue (antiviral pill) that has kept your hepatitis B virus undetectable for at least 24 weeks
- HBeAg negative (a specific hepatitis B marker) at screening
- No cirrhosis, liver cancer, or serious liver disease besides hepatitis B
- No recent cancer, major surgery, or significant heart or brain disease
- Able and willing to use effective birth control during the study
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 trial studies an injection (HRS-5635), either alone or with other medicines, to see if it is safe and helps keep chronic hepatitis B under control. It is for people who are already on standard hepatitis B antivirals and have low or undetectable viral levels.
This study tests a new experimental drug called AHB-171 in people with chronic hepatitis B infection. The trial aims to see how safe the drug is and how well it works to help control the virus.
This trial tests a new treatment (GST-HG131&141 tablets) versus a placebo for people with chronic hepatitis B. It aims to see if the treatment can better control the virus in those already on stable therapy.
This study tests a new drug called HH-006 to see if it can help treat chronic hepatitis B infection. Participants will be grouped by their infection level, and the study checks whether the drug is safe and works to reduce the hepatitis B virus.
This trial tests a new drug called GST-HG141 for people with chronic hepatitis B whose virus is still active despite taking standard antiviral pills. It aims to see if the new drug can better control the virus.
This study tests a new injection called AHB-137 in people with chronic hepatitis B who have never received antiviral treatment. The goal is to see if it can help reduce the hepatitis B virus in the body and improve liver health.
Hear when a new Nucleos(t)Ide Analogue-suppressed HBeAg-negative Patients With Chronic Hepatitis B trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.